Kudzai Kutukwa on Nostr: "Drug maker Gilead, which distributed the drug on a compassionate use basis to ...
"Drug maker Gilead, which distributed the drug on a compassionate use basis to several hundred patients globally, expects to start its own late-stage trials this month.
Remdesivir has so far been proven to inhibit the related virus Mers-CoV...There are currently no approved therapies for coronavirus, but many countries have been repurposing anti-virals in the the hope they might work against the infection."
https://archive.is/Qt2PB#selection-935.0-943.166Published at
2026-10-23 15:15:44 UTCEvent JSON
{
"id": "564c82ea6f58a467780201d45c39a08828aa39d4795eca97cb0678e5a36345b7",
"pubkey": "54609048284d2a151c8df625f40c389d423ed057fcef927db88956d28e22ba03",
"created_at": 1792768544,
"kind": 1,
"tags": [
[
"t",
"selection"
]
],
"content": "\"Drug maker Gilead, which distributed the drug on a compassionate use basis to several hundred patients globally, expects to start its own late-stage trials this month.\nRemdesivir has so far been proven to inhibit the related virus Mers-CoV...There are currently no approved therapies for coronavirus, but many countries have been repurposing anti-virals in the the hope they might work against the infection.\"\n\nhttps://archive.is/Qt2PB#selection-935.0-943.166",
"sig": "8ba01d8e1033820330b7be31661e74978171d698b1e9a9214b172efa6c1008254277bb05d9ac6e63811e20c57440271272f9863fe57378b2082dcd58b8b2d185"
}
